Valuation: PTC Therapeutics, Inc.

Market Cap 6.37B 5.6B 5.2B 4.78B 8.97B 614B 9.11B 61.81B 24.15B 302B 23.92B 23.41B 1,043B P/E 2026 *
104x
P/E 2027 * 29.6x
Enterprise Value 4.51B 3.96B 3.68B 3.38B 6.35B 434B 6.45B 43.76B 17.1B 214B 16.94B 16.57B 739B EV / Sales 2026 *
3.81x
EV / Sales 2027 * 3.29x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day-2.08%
1 week-2.25%
Current month-5.82%
1 month-9.10%
3 months+12.59%
6 months+2.09%
Current year+1.13%
1 week 76.59
Extreme 76.59
80.56
1 month 76.55
Extreme 76.55
90.87
Current year 61.43
Extreme 61.43
90.87
1 year 43.18
Extreme 43.175
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 21/03/2023
Director of Finance/CFO 41 12/07/2023
Chief Tech/Sci/R&D Officer - 30/09/2017
Director TitleAgeSince
Chairman 74 31/10/2004
Chairman 80 30/03/1998
Director/Board Member 65 30/11/2005
Date Insider Type Main position Quantity % Market Cap.
14/07/26 Sell

Chief Financial Officer

-3,494 0.0042%
09/07/26 Fiscal year

Director

47,502 0.0573%
09/07/26 Fiscal year

Chief Technology Officer

7,392 0.0089%
Change 5-day change 1-year change 3-year change Capi.($)
-2.08%-2.25%+71.70%+97.89% 6.37B
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
Average +0.23%+0.97%+30.75%+56.92% 364.99B
Weighted average by Cap. +0.76%+1.94%+36.06%+78.18%

Financials

2026 *2027 *
Net sales 1.18B 1.04B 966M 886M 1.67B 114B 1.69B 11.47B 4.48B 55.99B 4.44B 4.34B 194B 1.34B 1.18B 1.1B 1.01B 1.89B 129B 1.92B 13.03B 5.09B 63.62B 5.04B 4.94B 220B
Net income 51.95M 45.63M 42.43M 38.94M 73.16M 5B 74.29M 504M 197M 2.46B 195M 191M 8.5B 195M 171M 159M 146M 274M 18.74B 278M 1.89B 737M 9.21B 730M 715M 31.85B
Net Debt -1.86B -1.63B -1.52B -1.39B -2.62B -179B -2.66B -18.05B -7.05B -88.1B -6.99B -6.83B -305B -1.95B -1.71B -1.59B -1.46B -2.74B -188B -2.79B -18.91B -7.39B -92.28B -7.32B -7.16B -319B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
24/07/26 US$76.82 -2.08% 838,164
23/07/26 US$78.45 +0.06% 759,373
22/07/26 US$78.40 -0.13% 583,883
21/07/26 US$78.50 +0.63% 1,145,977
20/07/26 US$78.01 -0.74% 954,314
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
76.82USD
Average target price
96.07USD
Spread / Average Target
+25.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock